p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor D.N. Pollerl, C.E. Hutchings', M. Galea2, J.A. Bell', R.A. Nicholson3, C.W. Elston (d.f. = 1), P = 0.053 were identified. p53 protein expression is a common event in human breast cancer and is present in both DCIS and invasive mammary carcinoma. Abnormal expression of p53 protein is a feature of both in situ and invasive breast carcinoma, implying that the abnormal p53 protein expression may be implicated in the early stages of mammary carcinoma progression.
The human p53 gene protein is a nuclear phosphoprotein with a nuclear targeting sequence which directs p53 to the cell nucleus (Dang & Lee, 1989) . p53 protein was originally identified in extracts of transformed cells reacting with antiserum from animals innoculated with tumour cell lines transformed by simian virus 40 (SV 40) (Lane & Crawford, 1979; Linzer & Levine, 1979) . The p53 protein was also identified in chemically and retrovirus transformed cells where the protein is expressed at high levels due to protein stabilisation (Linzer & Levine, 1979; Melero et al., 1980) . The p53 gene is now thought to be a tumour suppressor gene, negatively regulating the cell cycle via the p53 gene protein and requiring loss of function mutations for tumour formation (Milner & Watson, 1991) . p53 gene mutation appears to be the most common gene mutation identified in carcinomas to date (Harris, 1991) with mutations of the p53 gene commonly seen in primary breast, colonic, ovarian, lung and oesophageal carcinomas (Hollstein et al., 1991) . The abnormal protein coded for by various p53 gene mutants (mutant p53 protein) is more stable and therefore has a much longer half life than the normal or 'wild type' p53 gene protein (Finlay et al., 1988) . This inherent stability allows detection of mutant p53 proteins using immunohistochemistry, the wild type being much harder to detect (Iggo et al., 1990) . There is now evidence that p53 mutation may not be the only mechanism implicated in expression of the p53 protein at the immunohistochemical level, and that altered or abnormal p53 degradation may also in certain situations be important in the immunocytochemical detection of p53 protein (WynfordThomas, 1992) . 'Wild-type' p53 protein is also detectable by immunohistochemistry in certain ras transformed rat thyroid cell lines (Wynford-Thomas, 1992) . The p53 gene is located on human chromosome 17pl3 (Isobe et al., 1986) , and partial or complete loss of one allele on chromsome 17p is frequently seen in human breast carcinoma (Mackay et al., 1988) .
The mechanism of wild type p53 function in normal cells is unknown, however in cells transfected with the wild type p53 gene, the wild type p53 protein may be able to activate gene transcription while the mutant p53 protein appears unable to activate transcription (Raycroft et al., 1991) . It has recently been suggested that the cell growth response involves a switch from a suppressor to a promoter conformational change in the p53 protein (Milner & Watson, 1990) . Complete absence of p53 protein in mice homozygous for a null mutant p53 allele has been recently shown to be compatible with embryonic development and survival of null mutant p53 mice to maturity (Donehower et al., 1992) .
A small number of previous studies have examined p53 protein expression in human mammary carcinoma utilising immunohistochemistry, showing p53 protein expression to be present in 27-54% of primary breast carcinomas (Bartek et al., 1990a; Cattoretti et al., 1988a, b; Davidoff et al., 1991b; Horak et al., 1991; Ostrowski et al., 1991; Walker et al., 1991) . Immunohistochemical expression of p53 protein is seen in neoplastic breast tissue but not in normal breast tissue and infrequently in atypical hyperplasias of the breast (Bartek et al., 1990a) .
Expression of the epidermal growth factor receptor (EGFR) and overexpression of the related oncogene protein c-erbB-2 have also been shown to be adverse prognostic factors in mammary carcinoma (Sainsbury et al., 1987; Slamon et al., 1989; Lovekin et al., 1991) . A statistically significant association between p53 protein expression and expression of EGFR in breast carcinoma has been reported in one series (Cattoretti et al., 1988a) although no significant association of p53 protein expression and expression of c-erbB-2 in breast carcinoma was noted in two other published series (Davidoff et al., 1991b; Walker et al., 1991) .
Our aim in this study was to examine the relationship of p53 protein expression, pathological tumour variables and patient survival in a well documented series of primary breast carcinomas. We also wished to examine the relationship of p53 protein expression, oestrogen receptor, EGFR and cerbB-2 protein expression in breast carcinoma and so to establish the relationship between the three latter well established prognostic factors and expression of p53; a novel tumour suppressor protein. As p53 gene mutations are thought to be a common event in breast cancer, then immunohistochemical expression of the p53 gene protein might also be an independent prognostic factor in human mammary carcinoma.
Materials and methods
Antibodies pAbl801 is a mouse monoclonal anti-p53 antibody (EuroPath Ltd, Bude, Cornwall, UK) which recognises an epitope near the N-terminus of both the wild and mutant forms of the human p53 protein (Banks et al., 1986) . EGFR-1, a mouse monoclonal anti-epidermal growth factor receptor antibody (Amersham Ltd, Amersham, UK) was utilised to examine expression of EGFR. Examination of overexpression of the c-erbB-2 protein was performed using the polyclonal rabbit antibody 21N (Venter et al., 1987) Table I ), five of nine carcinomas of mixed ductal and lobular type (55.5%) were p53 positive, six of 23 carcinomas of tubular-mixed type (26.1%) were p53 positive, one of 12 invasive classical lobular carcinomas (8.3%) was p53 positive, two of three carcinomas of lobular-mixed type (66.6%) were p53 positive, 0 of 2 tubular carcinomas were p53 positive (0%), a single medullary carcinoma was p53 positive (100%), and single mucoid carcinoma was p53 negative (0%). Of the remaining 11 cases of invasive mammary carcinoma of other special types five were p53 positive. Three cases of ductal carcinoma in situ were examined; one case (33.3%) being p53 positive. Table II ). Using chi-square analysis a highly statistically significant association of lack of tumour p53 protein expression and positive tumour oestrogen receptor protein status was identified, x2 = 19.78 (d.f. = 1), P< 0.001 (see Table III ). An association of p53 protein expression and tumour EGFR expression; x2 = 7.07 (d.f. = 1), P< 0.01 and positive tumour c-erbB-2 status was also seen X2 = 4.61 (d.f. = 1), P = 0.032 (see Table III ).
Clinicopathological associations and patient survival There was a trend towards significance of p53 expression and increased regional tumour recurrence in 143 patients on whom recurrence data was available x2 = 3.20 (d.f. = 1), P<0.001 (S) P = 0.16 (NS) P = 0.035 (S)a a(S) Statistically significant; (NS) Not statistically significant. Figure 2 ).
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Discussion
In this study of 149 cases of primary symptomatic breast carcinoma taken from the Nottingham/Tenovus Primary Breast Carcinoma Series (146 invasive carcinomas and three cases of DCIS) we have demonstrated a statistically significant association between expression of the p53 protein and high tumour grade, expression of EGFR, and c-erbB-2 protein overexpression. A strong negative association of p53 protein expression and positive tumour oestrogen receptor status was also identified. A non-statistically significant trend towards poorer survival was identified in the subgroup of 62 cases (42.5%) that showed p53 expression (see Figure 2) . Other groups have also found a similar association of p53 protein expression in breast carcinoma and high tumour grade (poor tumour differentiation) (Cattoretti et al., 1988a; Ostrowski et al., 1991; Walker et al., 1991) pressing the p53 protein noted in one other published series (Ostrowski et al., 1991) . A statistically significant association of p53 and c-erbB-2 overexpression was identified. This association has not been previously reported. Three other previous studies failed to find an association between p53 protein expression and cerbB-2 overexpression (Davidoff et al., 1991b; Horak et al., 1991; Walker et al., 1991) . A significant association between p53 and EGFR expression has been noted in two other published series (Cattoretti et al., 1988; Horak et al., 1991) .
Other authors have also reported a similar relationship of p53 protein expression and negative tumour oestrogen receptor status in breast carcinoma (Cattoretti et al., 1988a,b; Davidoff et al., 1991b; Walker et al., 1991) The results of immunohistochemical analysis of the p53 gene protein in both our own and in other series have shown that p53 protein expression in neoplastic cells is usually nuclear, although some tumour cell cytoplasmic staining may also be identifiable (Bartek et al., 1991; Cattoretti et al., 1988; Iggo et al., 1990) . Tumour cell p53 staining appears to be associated with p53 gene mutation, at least in some cases Iggo et al., 1990) , as well as in breast carcinoma cell lines (Bartek et al., 1990b) p53 protein expression may also be related to altered and abnormal p53 protein degradation in certain situations (Wynford-Thomas, 1992) . The presence of p53 protein expression in some cases of pure DCIS (one of three in our series) was also noted in three other series (Bartek et al., 1990a; Walker et al., 1991) . This finding supports the hypothesis that p53 protein expression and by inference p53 gene mutation is present in the early stages of human breast cancer. Davidoff et al. showed that two of 15 cases of pure DCIS in their series expressed high levels of p53 protein. Analysis of the p53 mRNA from one of these two cases by polymerase chain reaction demonstrated a p53 mRNA nucleotide substitution, infering altered the amino-acid composition of p53 protein . This implies that p53 gene mutations may be present in the early stages of breast cancer. Expression of the same mutant p53 mRNA was also identified in both the in situ and invasive components of the same breast carcinoma, implying that p53 gene mutations may be maintained in the progression of breast carcinoma from DCIS to invasive disease.
If the hypothesis that p53 gene mutation is an early event in breast carcinoma is correct it is not surprising that there is no association between p53 protein expression and lymph node tumour status, distant metastases, or local recurrence of carcinoma. Other series have also observed a similar lack of association of p53 protein expression and lymph node status (Cattoretti et al., 1988; Ostrowski et al., 1991; Walker et al., 1991) although an association of p53 expression and advanced lymph node status was reported by Davidoff et al. (199lb) . Our data showing a lack of association of p53 protein expression, presence of distant metastases and local tumour recurrence would also be consistent with our finding of a lack of association of p53 protein expression and breast primary tumour lymph nodal status as described above.
p53 gene mutations are relatively common in invasive breast carcinoma (Prosser et al., 1990; Thompson et al., 1990) and have also been identified in breast carcinoma cell lines (Bartek et al., 1990b) . The wild type p53 gene has been shown to act as a suppressor of cellular growth in human breast carcinoma cells, as shown by a study of MDA-MB468 and T47D breast carcinoma cell lines which contain the mutant p53 gene, but which then subsequently fail to grow after DNA transfection with the wild type p53 gene (Casey et al., 1991) .
Recent evidence points to clonal expansion of mutant p53 gene containing cells in the progression of primary brain tumours (Sidransky et al., 1992) , implying that tumour cells which show p53 gene mutations may have a selective growth advantage as compared to tumour cells without p53 gene mutations, as predicted by Nowell (1976) . Expression of the p53 gene protein appears to be a common event in human breast cancer and expression is directly related to poor tumour grade, epidermal growth factor receptor expression, c-erbB-2 protein overexpression, and negative tumour oestrogen receptor protein status.
We were unable to show that p53 protein expression is an independent prognostic factor for patient survival, although a near significant tendency towards poorer survival was seen in tumours that showed p53 protein expression. Our data would be consistent with p53 protein expression, and by inference p53 gene mutation or alteration in cellular p53 protein metabolism and degradation being an early event in human breast cancer. The recent observation that clonal expansion of mutant p53 containing tumour cell lineages occurs in primary cerebral gliomas would offer an attractive if incomplete explanation of our own findings if similar clonal expansion were also to occur in mammary carcinogenesis.
